|Bid||0.00 x 1300|
|Ask||0.00 x 1000|
|Day's Range||63.42 - 64.89|
|52 Week Range||51.88 - 112.25|
|Beta (3Y Monthly)||0.66|
|PE Ratio (TTM)||66.43|
|Earnings Date||Apr 24, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||77.00|
Counseling and resources available free-of-charge to local community
Magellan Health Inc NASDAQ/NGS:MGLNView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for MGLN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MGLN had net inflows of $3.67 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
It’s not often a high-profile activist investor comes to town, but one that quite often barges into boardrooms has appeared on our radar screen now that New York hedge fund Starboard Value LP has taken aim at a publicly traded company in the Valley.
One of the publicly traded company's largest shareholders, a seasoned corporate raider who has orchestrated shakeups multiple times, is seeking major changes to the board of directors.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
What’s Happening in e-Commerce: EBAY, JD, SHOP, ETSY, & PDDExploring options for StubHub and Classifieds businessesThis month, eBay (EBAY) announced some form of settlement with activist investors Elliott Management and Starboard Value. The
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Counseling and resources available free-of-charge to local community
Magellan Health, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2018, as summarized below:
Magellan Health, Inc. (MGLN) today acknowledged that Starboard Value LP (“Starboard”) has provided notice of its intent to nominate six candidates to stand for election to the Board of Directors at the Company’s 2019 Annual Meeting of Shareholders. Starboard stated that it expects that five of the Company's nine current Board members will be standing for election at the Annual Meeting, and if that remains the case, Starboard has indicated that it would withdraw one of its six director candidates.
Activist investor Starboard Value LP called on Magellan Health Inc. to explore "all potential strategic alternatives," including a sale of the company, to unlock shareholder value. Starboard, which said it owns 9.8% of the healthcare management company's outstanding shares, also nominated a "full slate" of candidates for election to Magellan's board. In an open letter to shareholders, Starboard said the company is "deeply undervalued," as operational missteps have resulted in "frustratingly extensive periods of share price underperformance." Among the execution issues Starboard listed were key legacy contract losses, bringing on "significant yet unprofitable" new business and "haphazard" execution in its pharmacy benefit management business. "When comparing a revised standalone plan to a sale of the company, it is crucial for the Board to appropriately assess the risks inherent in the internal plan and the time required to achieve that plan, compared to the certainty of a sale transaction," Starboard wrote in the letter. The stock, which was still inactive in premarket trade, has lost 25.5% over the past 12 months while the SPDR Health Care Select Sector ETF has climbed 9.2% and the S&P 500 has gained 2.6%.
NEW YORK , Feb. 22, 2019 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), one of the largest shareholders of Magellan Health, Inc. ("Magellan" or the ...
Magellan Health (MGLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
closed up Wednesday 11.43% to $72.45 on a Reuters report that said the healthcare management services company was facing pressure from hedge fund Starboard Value to sell itself. Starboard Value is the company's third-largest institutional investor, according to Yahoo Finance, with an 8.64% stake representing a value of about $120.5 million. Magellan, which is advised by Goldman Sachs Group, is in the early stages of considering acquisition interest, though there is no certainty that a deal will materialize, according to the report.
(Adds Ophir Energy, Alitalia, Bristol-Myers Squibb, Cemex, Tilray, Magellan Health, Verus Petroleum, Owens & Minor; Updates Bank Audi, Sainsbury) Feb 20 (Reuters) - The following bids, mergers, acquisitions ...
(Reuters) - U.S. healthcare plan and pharmacy benefits manager Magellan Health Inc will explore selling itself after coming under pressure to do so from activist hedge fund Starboard Value LP, people familiar ...
Magellan Rx Management, the pharmacy benefit management (PBM) division of Magellan Health, Inc. (MGLN) released its ninth annual Medical Pharmacy Trend ReportTM. The benchmark report is the industry’s premier detailed resource that offers data for analyzing medical benefit drug claims as well as current medical benefit drug management strategies. Commercial per-member-per-month (PMPM) medical drug spend increased 18 percent to $29.97, above the 14 percent average annual trend over the last five years.
Magellan Health, Inc. today announced that it will report its earnings for the fourth quarter and full year ended on December 31, 2018 at approximately 6:30 a.m. Eastern on Thursday, February 28, 2019.
Today we are going to look at Magellan Health, Inc. (NASDAQ:MGLN) to see whether it might be an attractive investment prospect. Specifically, we're going to calculate its Return On Capital Read More...